A selection of major announcements

1. Meituan spent HK$400 million to buy back 5.63 million shares on January 10

$MEITUAN-W (03690.HK)$An announcement was issued. On January 10, 2024, HK$400 million was spent to repurchase 5,628,500 shares at a repurchase price of HK$69.6-72.85 per share. On the same day, 12,500 shares were issued as a result of the exercise of share options.

2. Pharmaceutical Biology: 132 new projects were added in 2023, bringing the total number of projects to 698

$WUXI BIO (02269.HK)$The Hong Kong Stock Exchange issued an announcement stating that the company will attend the 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024. A briefing including some information on the company's business operations will be given at the conference. The company's business and financial situation remains strong. 132 new projects were added in 2023, bringing the total number of projects to 698 (including 9 Phase III and commercialized “winner” projects, and 24 CMO projects).

3. Shimao Group: cumulative contract sales of 42.82 billion yuan in 2323, a year-on-year decrease of 50.51%

$SHIMAO GROUP (00813.HK)$The Hong Kong Stock Exchange announced that in 2023, the Group's total contract sales volume was approximately RMB 42.82 billion, down 50.5% year on year; the Group's total contract sales area was approximately 2.95 million square meters. The average sales price for the whole year was RMB 145.32 million per square meter.

The Group's contract sales in December last year were about 2.81 billion yuan, a year-on-year decrease of 60.03%, and the contract sales area was 201,000 square meters. The average sales price is 13,963 yuan per square meter.

4. Fosun Pharmaceutical: Famotidine injection drug registration application accepted

$FOSUN PHARMA (02196.HK)$It was announced that the drug registration application for famotidine injections independently developed by Jinzhou Aohong Pharmaceutical Co., Ltd., a holding subsidiary of the company, was recently accepted by the State Drug Administration. The new drug is intended for treatment of upper gastrointestinal bleeding due to peptic ulcers, acute stress ulcers, and hemorrhagic gastritis.

5. Shanghai Fudan: Shares held by Shanghai Government and its co-actors, Shanghai Nianjin, are pending freezing

$SHANGHAI FUDAN (01385.HK)$An announcement was issued. As of January 10, 2024, Shanghai Zhengben held 39.182 million shares of the company, accounting for 4.784% of the company's total share capital; Shanghai Nianjin, one of Shanghai's concerted actors, held 3.632,500 shares of the company, accounting for 0.443% of the company's total share capital. Together, the two hold approximately 42.814,500 shares of the company, accounting for 5.227% of the company's total share capital, and are shareholders holding more than 5% of the company's shares. The aforementioned shares are all subject to judicial freeze/judicial marking. The pending freeze disclosed this time will not affect the company's daily operations and management.

Financial performance

$SA SA INT'L (00178.HK)$: Third-quarter revenue increased 36.7% year-on-year to HK$1,182 billion

Operational data

$SHIMAO GROUP (00813.HK)$The total cumulative contract sales for 2023 is approximately $42.82 billion

$YUZHOU GROUP (01628.HK)$The cumulative sales amount in 2023 was 17.836 billion yuan

$GANGLONG CHINA (06968.HK)$: In 2023, a total contract sales amount of 12.2 billion yuan was achieved

$POU SHENG INT'L (03813.HK)$: The net consolidated cumulative operating income of 2023 was 20.064 billion yuan, up 7.7% year-on-year

$CGN NEW ENERGY (01811.HK)$: The cumulative total power generation capacity of 19076.6 GWH in 2023 decreased by 0.6% year-on-year

$YUEXIUTRANSPORT (01052.HK)$: Humen Bridge toll revenue of 88.01 million yuan increased 65.1% year-on-year in November

$COFCO JOYCOME (01610.HK)$Operation Report: 753,000 pigs were released in December

$YUE YUEN IND (00551.HK)$: Net consolidated cumulative operating income of US$7.89 billion in 2023 decreased by 12.04% year-on-year

Important matters

$SDHS NEW ENERGY (01250.HK)$Joint venture approved 100MW market-based grid-connected project index in Jiangsu

$SHANGHAI FUDAN (01385.HK)$: The shares of the company held by Shanghai Government and its co-actors are all in a state of judicial freeze/judicial marking

$FOSUN PHARMA (02196.HK)$: Famotidine injection drug registration application accepted

$JUNSHI BIO (01877.HK)$LATEST ANNOUNCEMENT: Termination of licensing and commercialization agreement with Coherus

Increase or decrease holdings

$YADEA (01585.HK)$The controlling shareholder increased its holdings by a total of 290,000 shares

Repurchase cancellation

$TENCENT (00700.HK)$1.79 million shares were repurchased at HK$502 million on January 10

$MEITUAN-W (03690.HK)$5.63 million shares were repurchased at HK$400 million on January 10

$HSBC HOLDINGS (00005.HK)$On January 9, it cost HK$210 million to repurchase 3.298 million shares

$AIA (01299.HK)$2.16 million shares were repurchased at HK$135 million on January 10

$XIAOMI-W (01810.HK)$On January 10, it cost HK$49.14 million to buy back 3.5 million shares

$BEKE-W (02423.HK)$On January 9, it cost 5 million US dollars to buy back 1.01 million shares

$COSCO SHIP HOLD (01919.HK)$On January 10, it cost HK$20.35 million to repurchase 2.66 million shares

$ESR (01821.HK)$On January 10, 1,586,800 shares were purchased at HK$17.269,000

$KINGDEE INT'L (00268.HK)$On January 10, 1,287 million shares were repurchased at HK$12.872,800

$PRU (02378.HK)$On January 9, it cost £2.784 million to buy back 330,000 shares

$YUM CHINA (09987.HK)$On January 9, $2.4 million was spent to buy back 61,000 shares

$KINGSOFT (03888.HK)$On January 10, 458,600 shares were repurchased at HK$9.995,900

edit/new